Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 149 No. 0304 (2019)

Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions

  • Urs Rusch
  • Sarah Robbins
  • Homie Razavi
  • Pietro Vernazza
  • Sarah Blach
  • Philip Bruggmann
  • Beat Müllhaupt
  • Francesco Negro
  • David Semela
DOI
https://doi.org/10.4414/smw.2019.14694
Cite this as:
Swiss Med Wkly. 2019;149:w14694
Published
23.01.2019

Summary

BACKGROUND AND AIMS

Direct-acting antiviral agents have revolutionised hepatitis C treatment. In 2014, the Swiss Hepatitis Strategy was developed to eliminate hepatitis C virus (HCV) infection and the associated liver-related morbidity and mortality by 2030. Though numerous national studies and assessments have identified a relatively low prevalence rate of 0.7% in the country, little has been done to identify the epidemiology of HCV on the regional, or micro, level. This study aimed to identify scenarios to achieve the objectives of Swiss Hepatitis Strategy by 2030 in eastern, western and northern regions in Switzerland.

METHODS

Three Excel-based Markov disease burden models, based on hospital- and region-specific data, were developed to forecast the current and future prevalence of HCV infection by fibrosis stage and liver disease stage to 2030. Two scenarios were developed to evaluate the disease burden in St Gallen, Geneva and Zurich: a Base 2016 scenario, representing the current standard of care in each canton, and a second, potential scenario to achieve the Swiss Hepatitis Strategy goals.

RESULTS

In 2015, the estimated viraemic prevalence in St Gallen was 0.5% (0.5–0.6%) corresponding to 2800 (2600–3100) cases. In Geneva and Zurich, the estimated prevalence was slightly higher, with an estimated 0.7% (0.6–0.7%) viraemic prevalence, or 3300 (3000–3600) cases in Geneva and 0.7% (0.7–0.8%) viremic prevalence, or 10,800 (9900–11,900) infectionsin Zurich. In order to achieve the Swiss Hepatitis Strategy goals of a 30% reduction in new infections, total viraemic infections, liver transplants, and hepatocellular carcinoma cases by 2020 and a 90% reduction by 2030, all regions will need to increase the annual number of treated and diagnosed patients up to 2030. In St Gallen, an up-front investment to treat 430 patients annually by 2020 would be necessary, to achieve the 2020 goals. After 2020, treatment could be reduced to ~150 patients annually until 2030. The number of patients diagnosed, however, would need to be sustained at 130 annually after 2020. In Geneva, 235 patients need to be treated, with 140 diagnosed annually between 2019 and 2030 to achieve both 2020 and 2030 goals. In Zurich, 850 patients will need to be treated annually in 2019 and 2020 and the number of diagnosed will need to expand to 350 individuals annually by 2022.

CONCLUSIONS

Intensified screening for chronic hepatitis C and increased access to direct-acting antivirals are necessary to meet the Swiss hepatitis strategy elimination goals over the next 12 years.

References

  1. World Health Organization. Global hepatitis report 2017. Geneva, Switzerland: WHO; 2017.
  2. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al.; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76. doi:.https://doi.org/10.1016/S2468-1253(16)30181-9
  3. Swiss Hepatitis Strategy 2014-2030. Time to Act Now! Process Paper - A Living Document. http://www.hepatitis-schweiz.ch/files/Dokumente/Process_Paper_2nd_version_final.pdf. 2015.
  4. Swiss Federal Office of Public Health. [Situation Analysis of Hepatitis B and C in Switzerland.] Bern: Federal Office of Public Health; 2017.
  5. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60–89. doi:.https://doi.org/10.1111/jvh.12249
  6. Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. J Viral Hepat. 2015;22(s1, Suppl 1):46–73. doi:.https://doi.org/10.1111/jvh.12352
  7. Alfaleh FZ, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, et al. Strategies to manage hepatitis C virus infection disease burden - volume 3. J Viral Hepat. 2015;22(Suppl 4):42–65. doi:.https://doi.org/10.1111/jvh.12474
  8. Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, et al.; European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325–36. doi:.https://doi.org/10.1016/S2468-1253(17)30045-6
  9. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, et al. Strategies to manage hepatitis C virus infection disease burden-Volume 4. J Viral Hepat. 2017;24(Suppl 2):44–63. doi:.https://doi.org/10.1111/jvh.12759
  10. Lazarus JV, Wiktor S, Colombo M, Thursz M ; EASL International Liver Foundation. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–6. doi:.https://doi.org/10.1016/j.jhep.2017.06.033
  11. Polaris Observatory. [Internet] Cited 2017 September 1. Available from: http://polarisobservatory.org/.
  12. Federal Statistical Office FSO. Switzerland's population 2016. Neuchâtel: FSO;2017.
  13. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34–59. doi:.https://doi.org/10.1111/jvh.12248
  14. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm - volume 3. J Viral Hepat. 2015;22(Suppl 4):21–41. doi:.https://doi.org/10.1111/jvh.12476
  15. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm - volume 2. J Viral Hepat. 2015;22(Suppl 1):26–45. doi:.https://doi.org/10.1111/jvh.12351
  16. Bedossa P, Poynard T ; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289–93. doi:.https://doi.org/10.1002/hep.510240201
  17. Swiss Federal Office of Public Health (FOPH). Swiss mandatory notifications for hepatitis C per canton. FOPH/CD/EPI/RIC 29.08.2016. Berne: Swiss Federal Office of Public Health (FOPH); 2016.
  18. IMS Health International. 2015;Q1:
  19. Swiss hepatitis C cohort study report-March 31, 2012. [cited 3/7/2013]; Available from: http://www.swisshcv.ch/pdf/Report_SCCS_March_31_2012.pdf.
  20. Swiss hepatitis C cohort study. Study Population; Some salient features 2014. [cited 2014 4/15/2014]; Available from: http://www.swisshcv.ch/study-population.html.
  21. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82(4):546–55. doi:.https://doi.org/10.1002/jmv.21734
  22. Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, Butsashvili M, et al. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep. 2017;66(29):773–6. doi:.https://doi.org/10.15585/mmwr.mm6629a2
  23. Omran H. World Bank to lend Health ministry $200m for hepatitis C screening: minister, in Daily News Egypt. 2018: Egypt.
  24. Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, et al. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly. 2015;145:w14221. doi:.https://doi.org/10.4414/smw.2015.14221
  25. World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 Towards Ending Viral Hepatitis. Geneva: World Health Organization; 2016.
  26. Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. J Hepatol. 2018;68(5):932–9. doi:.https://doi.org/10.1016/j.jhep.2017.12.013
  27. Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One. 2015;10(6):e0125214. doi:.https://doi.org/10.1371/journal.pone.0125214
  28. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–70. doi:.https://doi.org/10.7326/0003-4819-156-4-201202210-00378
  29. Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107–16. doi:.https://doi.org/10.1016/j.drugpo.2017.07.006
  30. Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107–16. doi:.https://doi.org/10.1016/j.drugpo.2017.07.006
  31. Snow K, Scott N, Clothier HJ, MacLachlan JH, Cowie B. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis. Aust N Z J Public Health. 2017;41(2):193–8. doi:.https://doi.org/10.1111/1753-6405.12560
  32. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Euro Surveill. 2008;13(21):18881. doi:.https://doi.org/10.2807/ese.13.21.18881-en
  33. Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly. 2017;147:w14543.
  34. Salazar-Vizcaya L, Kouyos RD, Fehr J, Braun D, Estill J, Bernasconi E, et al.; Swiss HIV Cohort Study. On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study. J Viral Hepat. 2018;25(1):10–8. doi:.https://doi.org/10.1111/jvh.12752
  35. Braun DL, Hampel BH, Nguyen H, Flepp M, Stoeckle M, Beguelin C, et al. A treatment as prevention trial to eliminate HCV in HIV+ MSM: The Swiss HCVREE Trial. Conference on Retroviruses and Opportunistic Infections. 2018: Boston, Massachusetts.

Most read articles by the same author(s)

1 2 3 4 5 > >>